Overview

A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours

Status:
Recruiting
Trial end date:
2024-01-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to allow continued adavosertib treatment of patients with advanced solid tumours participating in the adavosertib clinical pharmacology studies and to assess the continued safety and tolerability of adavosertib for patients enrolled in adavosertib clinical pharmacology studies (hereafter referred to as the 'parent studies') who continue to use the therapy.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Collaborator:
Parexel
Treatments:
Adavosertib
MK-1775